Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor

Medical Oncology

Volumn 26, Issue 2, 2009, Pages 170-177

  Li, Wei ^a   Xu, Ru Jun ^a   Lin, Zhen Yun ^a   Zhuo, Guang Chao ^a   Zhang, Hong He ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cyclooxygenase; Ibuprofen; Ovarian cancer; SC 560

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CYCLOOXYGENASE 1 INHIBITOR; IBUPROFEN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1; PTGS1 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER INHIBITION; CANCER MODEL; DRUG EFFECT; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UPREGULATION; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IBUPROFEN; MICE; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PYRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651040709     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9104-9     Document Type: Article

References (47)

1. RF Ozols 2002 Future directions in the treatment of ovarian cancer Semin Oncol 29 32 42 10.1053/sonc.2002.31594 11840418 10.1053/sonc.2002.31594 1:CAS:528:DC%2BD38XitVKitLY%3D
2. NIH Consensus Development Panel on Ovarian Cancer 1995 NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up JAMA 273 491 7 10.1001/jama.273.6.491 10.1001/jama.273.6.491
3. AJ Dannenberg K Subbaramaiah 2003 Targeting cyclooxygenase-2 in human neoplasia: rationale and promise Cancer Cell 4 431 6 10.1016/S1535-6108(03) 00310-6 14706335 10.1016/S1535-6108(03)00310-6 1:CAS:528:DC%2BD2cXitFKquw%3D%3D (Pubitemid 38050040)
4. JR Vane YS Bakhle RM Botting 1998 Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 97 120 10.1146/annurev.pharmtox.38.1.97 9597150 10.1146/annurev.pharmtox.38.1.97 1:CAS:528:DyaK1cXivF2itro%3D
5. P Needleman J Turk BA Jakschik AR Morrison JB Lefkowith 1986 Arachidonic acid metabolism Annu Rev Biochem 55 69 1020 10.1146/annurev.bi.55.070186.000441 3017195 10.1146/annurev.bi.55.070186.000441 1:CAS:528:DyaL28XltFaru7g%3D
6. K Seibert J Masferrer Y Zhang K Leahy S Hauser J Gierse 1995 Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase Adv Prostaglandin Thromboxane Leukot Res 23 125 7 7794421 1:CAS:528: DyaK2MXktFOhsbY%3D
7. CJ Smith, et al. 1998 Pharmacological analysis of cyclooxygenase-1 in inflammation Proc Natl Acad Sci USA 95 13313 8 10.1073/pnas.95.22.13313 9789085 10.1073/pnas.95.22.13313 1:CAS:528:DyaK1cXntFWrsLY%3D (Pubitemid 28509568)
8. RS Sandler 1996 Epidemiology and risk factors for colorectal cancer Gastroenterol Clin North Am 25 717 35 10.1016/S0889-8553(05)70271-5 8960889 10.1016/S0889-8553(05)70271-5 1:STN:280:DyaK2s7itVaiug%3D%3D (Pubitemid 27022912)
9. DW Cramer BL Harlow L Titus-Ernstoff K Bohlke WR Welch ER Greenberg 1998 Over-the-counter analgesics and risk of ovarian cancer Lancet 351 104 7 10.1016/S0140-6736(97)08064-1 9439495 10.1016/S0140-6736(97)08064-1 1:STN:280:DyaK1c7gt1Klug%3D%3D (Pubitemid 28026637)
10. RE Harris S Kasbari WB Farrar 1999 Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer Oncol Rep 6 71 3 9864404 1:CAS:528:DyaK1MXkt1SjtA%3D%3D
11. RA Gupta, et al. 2003 Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer Cancer Res 63 906 11 12615701 1:CAS:528:DC%2BD3sXhs1agtbw%3D
12. T Daikoku, et al. 2006 Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer Cancer Res 66 2527 31 10.1158/0008-5472.CAN-05-4063 16510568 10.1158/0008-5472.CAN-05-4063 1:CAS:528:DC%2BD28XhvV2htL8%3D
13. T Daikoku, et al. 2005 Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer Cancer Res 65 3735 44 10.1158/0008-5472.CAN-04-3814 15867369 10.1158/0008-5472.CAN-04-3814 1:CAS:528:DC%2BD2MXjslGksr8%3D (Pubitemid 40616351)
14. J Reese X Zhao WG Ma N Brown TJ Maziasz SK Dey 2001 Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice Endocrinology 142 3198 206 10.1210/en.142.7.3198 11416042 10.1210/en.142.7.3198 1:CAS:528: DC%2BD3MXksleltLw%3D (Pubitemid 32575557)
15. CS Williams AJM Watson H Sheng R Helou J Sha RN DuBois 2000 Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models Cancer Res 60 6045 51 11085526 1:CAS:528:DC%2BD3cXotV2lsLw%3D
16. C Ovidiu, et al. 2002 Masferrer cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 Cancer Res 62 5778 84
17. W Li RJ Xu LH Jiang JF Shi X Long B Fan 2005 Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma Med Oncol 22 63 70 10.1385/MO:22:1:063 15750198 10.1385/MO:22:1:063
18. N Weidner JP Semple WR Welch J Folkman 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1875 87 10.1093/jnci/84.24.1875 1281237 10.1093/jnci/84.24.1875 1:STN:280:DyaK3s%2FpsFWhtA%3D%3D
19. A Seki J Kodama Y Miyagi S Kamimura M Yoshinouchi T Kudo 1997 Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas Int J Cancer 73 33 7 10.1002/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0. CO;2-2 9334806 10.1002/(SICI)1097-0215(19970926)73:1<33::AID-IJC6>3.0. CO;2-2 1:CAS:528:DyaK2sXmvFegurk%3D (Pubitemid 27445987)
20. Y Min, et al. 2005 Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer Clin Cancer Res 11 1618 28 10.1158/1078-0432.CCR-04-1696 10.1158/1078-0432.CCR-04-1696 (Pubitemid 40315247)
21. M Tsujii S Kawano S Tsuji H Sawaoka M Hori RN DuBois 1998 Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 705 16 10.1016/S0092-8674(00)81433-6 9630216 10.1016/S0092-8674(00)81433-6 1:CAS:528:DyaK1cXjsl2ksbw%3D (Pubitemid 28257578)
22. N Kirsi R Ari M Martin S Elizabeth CH Christian HT Timothy 1997 Transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression J Biol Chem 272 21455 60 10.1074/jbc.272.34.21455 10.1074/jbc.272.34.21455 (Pubitemid 27374017)
23. T Kitamura M Itoh T Noda M Matsuura K Wakabayashi 2004 Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal Int J Cancer 109 576 80 10.1002/ijc.20012 14991580 10.1002/ijc.20012 1:CAS:528:DC%2BD2cXislCis74%3D (Pubitemid 38339649)
24. Y Yokoyama M Dhanabal AW Griffioen VP Sukhatme S Ramakrishnan 2000 Synergy between angiostatin and endostatin: inhibitor of ovarian cancer growth Cancer Res 60 2190 6 10786683 1:CAS:528:DC%2BD3cXivVaksbo%3D
25. CV Rao C Indranie B Simi PT Manning JR Connor BS Reddy 2002 Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor Cancer Res 62 165 70 11782374 1:CAS:528:DC%2BD38XntV2iug%3D%3D
26. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 6 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D
27. Al Feldman SK Libutti 2000 Progress in antiangiogenic gene therapy of cancer Cancer 89 1181 94 10.1002/1097-0142(20000915)89:6<1181::AID- CNCR1>3.0.CO;2-T 11002212 10.1002/1097-0142(20000915)89:6<1181::AID- CNCR1>3.0.CO;2-T 1:CAS:528:DC%2BD3cXmvV2murg%3D
28. J Folkman 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 4 6 10.1093/jnci/82.1.4 1688381 10.1093/jnci/82.1.4 1:STN:280:DyaK3c%2FnvF2qug%3D%3D
29. TA Olson D Mohanraj LF Carson S Ramakrishnan 1994 Vascular permeability factor gene expression in normal and neoplastic ovaries Cancer Res 54 276 80 8261452 1:CAS:528:DyaK2cXhtVemtrc%3D
30. J Yoneda H Kuniyasu MA Crispens JE Price CD Bucana IJ Fidler 1998 Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice J Natl Cancer Inst 90 447 54 10.1093/jnci/90.6.447 9521169 10.1093/jnci/90.6.447 1:CAS:528:DyaK1cXitlejtbg%3D
31. EM Hartenbach TA Olson JJ Goswitz D Mohanraj LB Twiggs LF Carson 1997 Vascular endothelial growth factor expression and survival in human epithelial ovarian carcinomas Cancer Lett 121 169 75 10.1016/S0304-3835(97)00350-9 9570355 10.1016/S0304-3835(97)00350-9 1:CAS:528:DyaK2sXntlCiu70%3D (Pubitemid 28008916)
32. PJ Paley, et al. 1997 Vascular endothelial growth factor expression in early stage 1 ovarian carcinomas Cancer (Phila) 80 98 106 10.1002/(SICI)1097- 0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A 10.1002/(SICI)1097- 0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A 1:STN:280: DyaK2szlsVChsg%3D%3D (Pubitemid 27270925)
33. TA Olson D Mohanraj S Roy S Ramakrishnan 1997 Targeting the tumor vascular: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate Int J Cancer 73 865 70 10.1002/(SICI)1097-0215(19971210) 73:6<865::AID-IJC17>3.0.CO;2-3 9399667 10.1002/(SICI)1097-0215(19971210) 73:6<865::AID-IJC17>3.0.CO;2-3 1:CAS:528:DyaK2sXnslOqs78%3D
34. JA Nagy SM Ellen TH Kemp JM Eleanor MD Ann FD Harold 1995 Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining Cancer Res 55 376 85 7529135 1:CAS:528: DyaK2MXjtFyjsbk%3D
35. CE Bryant I Appleton JA Mitchell 1998 Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells Life Sci 62 2195 201 10.1016/S0024-3205(98)00197-0 9627078 10.1016/S0024-3205(98)00197-0 1:CAS:528:DyaK1cXjtF2nsbo%3D (Pubitemid 28248436)
36. 2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors J Lipid Res 41 873 81 10828079 1:CAS:528:DC%2BD3cXkt1aktLw%3D
37. RN Dubois SB Abramson L Crofford 1998 Cyclooxygenase in biology and disease FASEB J 12 1063 73 9737710 1:CAS:528:DyaK1cXlvFWntbY%3D
38. 2 level and ornithine decarboxylase activity at the promotion phase of lung tumorigenesis in mice Biochem Pharmacol 53 1757 9 10.1016/S0006-2952(96)00869-6 9264330 10.1016/S0006-2952(96)00869-6 1:CAS:528:DyaK2sXlt1Sns7g%3D (Pubitemid 27356107)
39. D Hanahan J Folkma 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353 64 10.1016/S0092-8674(00) 80108-7 8756718 10.1016/S0092-8674(00)80108-7 1:CAS:528:DyaK28XltVSks7s%3D (Pubitemid 26272076)
40. JL Masferrer A Koki K Seibert 1999 Cox-2 inhibitors, a new class of antiangiogenic agents Ann NY Acad Sci 889 84 6 10.1111/j.1749-6632.1999.tb08726. x 10668485 10.1111/j.1749-6632.1999.tb08726.x 1:CAS:528:DC%2BD3cXnt1Smsg%3D%3D
41. JL Masferrer, et al. 2000 Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 1306 11 10728691 1:CAS:528: DC%2BD3cXhvFWrt74%3D
42. N Ferrara 1995 The role of vascular endothelial growth factor in pathological angiogenesis Breast Cancer Res Treat 36 127 37 10.1007/BF00666035 8534862 10.1007/BF00666035 1:STN:280:DyaK28%2FkvFOqug%3D%3D
43. S Yamamoto, et al. 1997 Expression of vascular endothelial growth factor (VEGF) in epithelia ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels Br J Cancer 76 1221 7 9365173 1:STN:280:DyaK1c%2FjtVCmtw%3D%3D
44. N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 8 1701519 1:STN:280:DyaK3M%2FnsVWquw%3D%3D
45. N Ferrara 1999 Vascular endothelial growth factor: molecular and biological aspects Curr Top Microbiol Immunol 237 1 30 9893343 1:CAS:528:DyaK1MXitVKhug%3D%3D (Pubitemid 28554856)
46. JL Wallace W McKnight BK Reuter N Vergnolle 2000 NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2 Gastroenterology 119 706 14 10.1053/gast.2000.16510 10982765 10.1053/gast.2000.16510 1:CAS:528:DC%2BD3cXmslSrsr0%3D
47. T Kitamura, et al. 2002 Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis Carcinogenesis 23 1463 6 10.1093/carcin/23.9.1463 12189188 10.1093/carcin/23.9. 1463 1:CAS:528:DC%2BD38Xms1Kntrg%3D